Oxford Biomedica (OXB) Stock Overview
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for OXB from our risk checks.
OXB Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Oxford Biomedica plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£4.30 |
| 52 Week High | UK£4.72 |
| 52 Week Low | UK£2.33 |
| Beta | 0.90 |
| 1 Month Change | 22.16% |
| 3 Month Change | 47.26% |
| 1 Year Change | 22.51% |
| 3 Year Change | -14.00% |
| 5 Year Change | -49.05% |
| Change since IPO | -82.97% |
Recent News & Updates
Recent updates
Oxford Biomedica plc's (LON:OXB) Price Is Right But Growth Is Lacking After Shares Rocket 30%
Jul 29
CDMO Expansion Will Widen Global Cell And Gene Therapy Access
Expansion into AAV and other vector types reduces dependency risks and supports earnings growth through diversified revenue streams.Health Check: How Prudently Does Oxford Biomedica (LON:OXB) Use Debt?
Apr 10Oxford Biomedica plc (LON:OXB) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Feb 28Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?
Oct 19Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%
Aug 23Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 15Is Oxford Biomedica (LON:OXB) Using Too Much Debt?
Oct 06Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings
May 02Shareholder Returns
| OXB | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -7.0% | -1.0% | 3.2% |
| 1Y | 22.5% | 1.5% | 16.4% |
Return vs Industry: OXB exceeded the UK Biotechs industry which returned 1.5% over the past year.
Return vs Market: OXB exceeded the UK Market which returned 16.4% over the past year.
Price Volatility
| OXB volatility | |
|---|---|
| OXB Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: OXB has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: OXB's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 850 | Frank Mathias | www.oxb.com |
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product.
Oxford Biomedica plc Fundamentals Summary
| OXB fundamental statistics | |
|---|---|
| Market cap | UK£467.81m |
| Earnings (TTM) | -UK£43.19m |
| Revenue (TTM) | UK£128.80m |
Is OXB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OXB income statement (TTM) | |
|---|---|
| Revenue | UK£128.80m |
| Cost of Revenue | UK£75.78m |
| Gross Profit | UK£53.02m |
| Other Expenses | UK£96.21m |
| Earnings | -UK£43.19m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Sep 23, 2025
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 41.17% |
| Net Profit Margin | -33.53% |
| Debt/Equity Ratio | 66.2% |
How did OXB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/11 21:54 |
| End of Day Share Price | 2025/08/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oxford Biomedica plc is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kane Slutzkin | Deutsche Bank |
| Susie Jana | Edison Investment Research |
| Jens Lindqvist | Investec Bank plc (UK) |